论文部分内容阅读
目的探讨利妥昔单抗(抗CD20单抗)治疗难治性免疫性血小板减少性紫癜(ITP)的安全性和有效性。方法应用利妥昔单抗(375mg/m2,静脉输注,每周1次,连用4周)治疗31例难治性ITP患者。结果 10例获完全缓解(32.3%),13例获部分缓解(41.9%),5例微效(16.1%),3例无效(9.7%)。均无明显不良反应。结论利妥昔单抗可能是治疗难治性ITP安全、有效的药物。
Objective To investigate the safety and efficacy of rituximab (anti-CD20 monoclonal antibody) in the treatment of refractory immune thrombocytopenic purpura (ITP). Methods Rituximab (375mg / m2, intravenous infusion once a week for 4 weeks) was used to treat 31 patients with refractory ITP. Results The complete remission was achieved in 10 cases (32.3%), partial remission in 13 cases (41.9%), minor cases in 5 cases (16.1%) and ineffective in 3 cases (9.7%). No obvious adverse reactions. Conclusion Rituximab may be a safe and effective drug for the treatment of refractory ITP.